Syndax Pharmaceuticals (SNDX) Receivables - Other (2015 - 2026)

Syndax Pharmaceuticals' Receivables - Other history runs 12 years deep, the most recent figure standing at $24.7 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 139.81% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (up 139.81% YoY), while the FY2025 annual figure was $28.1 million, up 673.04% from the prior year.
• Receivables - Other for Q1 2026 stood at $24.7 million, up from $6.4 million in the prior quarter.
• The five-year high for Receivables - Other was $24.7 million in Q1 2026, with the low at $158000.0 in Q1 2022.
• The 5-year median for Receivables - Other is $3.5 million (2024), against an average of $6.2 million.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other jumped 2393.96% in 2022, then sank 82.64% in 2023.
• Syndax Pharmaceuticals' Receivables - Other stood at $3.5 million in 2022, then slumped by 64.68% to $1.2 million in 2023, then soared by 196.25% to $3.6 million in 2024, then jumped by 76.18% to $6.4 million in 2025, then jumped by 285.7% to $24.7 million in 2026.
• Business Quant data shows SNDX's Receivables - Other at $24.7 million in Q1 2026, $6.4 million in Q4 2025, and $20.9 million in Q3 2025.